A
Andreessen Horowitz LLC
+ HoldingBRVE
+1.99%
3M Return
$21.440
-0.041 (-0.19%)At close
Loading chart…
- High
- 21.530
- Open
- 21.450
- VWAP
- 21.18
- Volume
- 119.56K
- Mkt Cap
- —
- Low
- 20.580
- Amount
- 2.53M
- EV/EBITDA, TTM
- 0.00
Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart.
AI analysis of Braveheart Bio, Inc. (BRVE)
BuyBraveheart Bio, Inc. (BRVE) appears to be a good buy right now due to its recent price of $21.44, which is significantly below the analyst price targets ranging from $40 to $48. The stock has shown a strong 5-day change of +14.59%, indicating positive momentum. Additionally, the RSI is at 65.87, suggesting that while the stock is nearing overbought territory, it still has room for growth. The main risk is the substantial net loss reported for Q2 2026 of $18.60 million, which could impact future performance if not managed effectively.
Valuation Metrics
The current forward P/E ratio for Braveheart Bio, Inc. (BRVE) is 0.00, compared to its 5-year average forward P/E of .
Whales holding BRVE
Events Timeline
News
9.509-09NASDAQ.COMBraveheart Bio Reports Wider Q2 Loss Amid Clinical Advancements
8.509-01renaissancecapitalSix IPOs and Five SPACs Priced This Week
- 8.509-01renaissancecapital
IPO and SPAC Market Dynamics This Week
8.509-01renaissancecapitalAugust IPO Market Review and Outlook
8.509-01renaissancecapitalAugust IPO Market Review and Outlook
BRVE FAQ — answered by Alphio AI
Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart. It operates in the Healthcare sector.
Braveheart Bio, Inc. (BRVE) appears to be a good buy right now due to its recent price of $21.44, which is significantly below the analyst price targets ranging from $40 to $48. The stock has shown a strong 5-day change of +14.59%, indicating positive momentum. Additionally, the RSI is at 65.87, suggesting that while the stock is nearing overbought territory, it still has room for growth. The main risk is the substantial net loss reported for Q2 2026 of $18.60 million, which could impact future performance if not managed effectively.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.